© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
VEGF-mediated angiogenesis is impaired by angiotensin type 1 receptor blockade in cardiomyopathic hamster hearts
Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan
* Corresponding author. Tel.: +81-11-716-1161; fax: +81-11-706-7874. okamotoh{at}hucc.hokudai.ac.jp
Objective: Coronary microcirculation plays an important role in the progression of cardiac remodeling. Among angiogenic factors, it has been reported that angiotensin II may contribute to neovascularization. However, it is unknown whether inhibition of the renin–angiotensin system suppresses angiogenesis, especially within the heart. Our aim was to evaluate the effects of the angiotensin-converting enzyme inhibitor enalapril and the angiotensin II receptor type I blocker valsartan on cardiac microvasculature, function, vascular endothelial growth factor (VEGF) expression, and survival in cardiomyopathic hamsters. Methods: Male cardiomyopathic hamsters (BIO TO2) were administered either a placebo (group C), enalapril (30 mg/kg/day) (group E), or valsartan (40 mg/kg/day) (group V), starting at the age of 6 weeks. This continued until death. Hemodynamic study, histological analysis, and northern blot analysis were performed at 39 weeks. Results: Group V showed significant increases in percent fibrosis, end diastolic pressure, and LV dP/dt min, and significant decreases in percent fractional shortening, LV dP/dt max, capillary density, and the level of mRNA expression of VEGF compared with group C. Group E showed significant increases in percent fractional shortening while the capillary density and level of mRNA expression of VEGF were unchanged. The 300-day survival rate was significantly lower in group V (25.0%) but higher in group E (100%) than that of group C (66.7%). Conclusions: Therapy with valsartan may have adverse effects on survival rate concomitant with the progression of cardiac remodeling owing to impaired VEGF-mediated angiogenesis. Therapy with enalapril has a neutral effect on VEGF-mediated angiogenesis, leading to the suppression of cardiac remodeling and an increase in life expectancy.
KEYWORDS %FS, percent fractional shortening; ACEI, angiotensin-converting enzyme inhibitor; AII, angiotensin II; ARB, angiotensin type I receptor blockade; AST, asparaginate amino transferase; ATI receptor, angiotensin type I receptor; BK, bradykinin; BW, body weight; Cr, creatinine; DAB, 3',3'-diaminobenzidine; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GSA-B4, the lectin Griffonia simplicifolia; HR, heart rate; LV, left ventricular; LV dP/dt max, the maximum rate of rise in left ventricular pressure; LV dP/dt min, the maximum rate of fall in left ventricular pressure; LVDd, left ventricular end-diastolic dimension; LVEDP, left ventricular end-diastolic pressure; LVSP, left ventricular systolic pressure; LVW, left ventricular weight; NO, nitric oxide; PBS, phosphate-buffered saline; PG, prostaglandins; RAS, the renin–angiotensin system; SR, synchrotron radiation; VEGF, vascular endothelial growth factor
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
G. E. Gonzalez, I. M. Seropian, M. L. Krieger, J. Palleiro, M. A. Lopez Verrilli, M. M. Gironacci, S. Cavallero, L. Wilensky, V. H. Tomasi, R. J. Gelpi, et al. Effect of early versus late AT1 receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H375 - H386. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kondoh, Y. Sawa, N. Fukushima, G. Matsumiya, S. Miyagawa, S. Kitagawa-Sakakida, Y. Imanishi, N. Kawaguchi, N. Matsuura, and H. Matsuda Combined Strategy Using Myoblasts and Hepatocyte Growth Factor in Dilated Cardiomyopathic Hamsters Ann. Thorac. Surg., July 1, 2007; 84(1): 134 - 141. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ribatti, M. T. Conconi, and G. G. Nussdorfer Nonclassic Endogenous Novel Regulators of Angiogenesis Pharmacol. Rev., June 1, 2007; 59(2): 185 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Rakusan, Z. Chvojkova, P. Oliviero, I. Ostadalova, F. Kolar, C. Chassagne, J.-L. Samuel, and B. Ostadal ANG II type 1 receptor antagonist irbesartan inhibits coronary angiogenesis stimulated by chronic intermittent hypoxia in neonatal rats Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1237 - H1244. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ushio-Fukai Redox signaling in angiogenesis: Role of NADPH oxidase Cardiovasc Res, July 15, 2006; 71(2): 226 - 235. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Dechend, V. Homuth, G. Wallukat, D. N. Muller, M. Krause, J. Dudenhausen, H. Haller, and F. C. Luft Agonistic Antibodies Directed at the Angiotensin II, AT1 Receptor in Preeclampsia Reproductive Sciences, February 1, 2006; 13(2): 79 - 86. [Abstract] [PDF] |
||||
![]() |
H. Kondoh, Y. Sawa, S. Miyagawa, S. Sakakida-Kitagawa, I. A. Memon, N. Kawaguchi, N. Matsuura, T. Shimizu, T. Okano, and H. Matsuda Longer preservation of cardiac performance by sheet-shaped myoblast implantation in dilated cardiomyopathic hamsters Cardiovasc Res, February 1, 2006; 69(2): 466 - 475. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Xu, K. Nagata, K. Obata, S. Ichihara, H. Izawa, A. Noda, T. Nagasaka, M. Iwase, T. Naoe, T. Murohara, et al. Nicorandil Promotes Myocardial Capillary and Arteriolar Growth in the Failing Heart of Dahl Salt-Sensitive Hypertensive Rats Hypertension, October 1, 2005; 46(4): 719 - 724. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kondoh, Y. Sawa, N. Fukushima, G. Matsumiya, S. Miyagawa, S. Kitagawa-Sakakida, I. A. Memon, N. Kawaguchi, N. Matsuura, and H. Matsuda Reorganization of cytoskeletal proteins and prolonged life expectancy caused by hepatocyte growth factor in a hamster model of late-phase dilated cardiomyopathy J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 295 - 302. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Davison, V. Homuth, A. Jeyabalan, K. P. Conrad, S. A. Karumanchi, S. Quaggin, R. Dechend, and F. C. Luft New Aspects in the Pathophysiology of Preeclampsia J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2440 - 2448. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. C. Luft Pieces of the preeclampsia puzzle Nephrol. Dial. Transplant., November 1, 2003; 18(11): 2209 - 2210. [Full Text] [PDF] |
||||








